Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
339
datasets available to search
ShareScore release 0.9.0
Dataset results
339 results for “CML”
A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML
ClinicalTrials.gov study NCT05341050. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)
ClinicalTrials.gov study NCT02842320. IPD Sharing: NO. Countries: 1. Publications: 0.
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndr
ClinicalTrials.gov study NCT00038805. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib
ClinicalTrials.gov study NCT02348957. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib
ClinicalTrials.gov study NCT01562847. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
ClinicalTrials.gov study NCT00069992. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
ClinicalTrials.gov study NCT06390306. IPD Sharing: NO. Countries: 1. Publications: 0.
Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib
ClinicalTrials.gov study NCT04681820. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients
ClinicalTrials.gov study NCT02253277. IPD Sharing: NO. Countries: 1. Publications: 0.
Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
ClinicalTrials.gov study NCT06665412. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of Olverembatinib (HQP1351) in Patients With CP-CML
ClinicalTrials.gov study NCT06423911. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients
ClinicalTrials.gov study NCT01578213. IPD Sharing: Not stated. Countries: 5. Publications: 0.
Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors
ClinicalTrials.gov study NCT01752062. IPD Sharing: NO. Countries: 1. Publications: 0.
Nilotinib for First-line Newly Diagnosed CML-CP Patients
ClinicalTrials.gov study NCT03942094. IPD Sharing: NO. Countries: 1. Publications: 0.
Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
ClinicalTrials.gov study NCT04621851. IPD Sharing: Not stated. Countries: 4. Publications: 0.
Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase
ClinicalTrials.gov study NCT00027144. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Reduced Intensity AlloSCT in(CML) With Persistent Disease
ClinicalTrials.gov study NCT00531310. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Frontline Asciminib Combination in Chronic Phase CML
ClinicalTrials.gov study NCT03906292. IPD Sharing: NO. Countries: 1. Publications: 0.
Tasigna in Glivec-resistant or Intolerant Patients in CML
ClinicalTrials.gov study NCT01206088. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
ClinicalTrials.gov study NCT03885830. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.